IMIDomics, Inc. is a biotechnology company focused on the discovery and development of new medicines for the treatment of immune-mediated inflammatory diseases (IMIDs).
Location: Spain, Catalonia, Barcelona
Employees: 11-50
Total raised: $16.5M
Investors 1
| Date | Name | Website |
| - | DNS Capita... | dnscap.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.07.2021 | Series A | $16.5M | - |
Mentions in press and media 7
| Date | Title | Description |
| 28.07.2021 | TPG and Brookfield add billions to the climate-tech coffers | As interest in climate-tech grows, so are the mega war chests. Paid Content Building a world economy in WordPress From WP Engine Growth equity and buyout investor TPG announced earlier this week that it had raised $5.4 billion to invest in ... |
| 28.07.2021 | TPG and Brookfield add billions to the climate-tech coffers | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. As interest in climate-tech grows, so are the mega war chests. Growth equity and buyout investor ... |
| 28.07.2021 | IMIDomics cierra una ronda de $16,5M a la que acuden DNS Capital, Bristol Myers, The Pritzker Organization y TAO Capital, entre otros | 28/07/2021 Nota de prensa IMIDOMICS, UN SPIN-OFF DEL VALL D’HEBRON, CONSIGUE $16,5M PARA DESARROLLAR NUEVOS FÁRMACOS CONTRA LAS ENFERMEDADES INFLAMATORIAS INMUNOMEDIADAS. IMIDomics, una spin-off de Vall d’Hebron, ha cerrado una ronda de ... |
| 27.07.2021 | IMIDomics emerges with $16.5M, former Takeda exec at the helm, and a precision approach to inflammatory disease Clinical Quality Oversight Forum | After 15 years of laying the groundwork, IMIDomics is coming out of the shadows with $16.5 million and a mission to bring precision medicine to inflammatory ailments such as Crohn’s disease, lupus and rheumatoid arthritis. RELATED: PureTech... |
| 27.07.2021 | IMIDomics :TM Closes $16.5 Million Series A Financing to Advance its Precision Discovery Platform for Immune-Mediated Inflammatory Diseases | IMIDomics Inc., a drug discovery company focused on patients with immune-mediated inflammatory diseases (IMIDs), has announced the completion of a $16.5 million Series A financing round. The round was led by DNS Capital with additional inve... |
| 27.07.2021 | IMIDomics emerges with $16.5M, former Takeda exec at the helm, and a precision approach to inflammatory disease | After 15 years of laying the groundwork, IMIDomics is coming out of the shadows with $16.5 million and a mission to bring precision medicine to inflammatory ailments such as Crohn’s disease, lupus and rheumatoid arthritis. It will do so wit... |
| 27.07.2021 | IMIDomics Completes $16.5M Series A Financing | IMIDomics Inc., a San Francisco, CA-based drug discovery company focused on patients with immune-mediated inflammatory diseases (IMIDs), completed a $16.5m Series A financing round. The round was led by DNS Capital with additional investmen... |